AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy

204
13
Favorite

AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy

Tiger Newspress2022-02-22

AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

204

Report

Comment（13）

QQXTZ
·2022-02-23
[Like] [Like]
Reply
2
Report
Fold Replies
- Squid:
  👍👍
  2022-02-23
  Reply
  Report
- Cockatoo:
  👍
  2022-02-23
  Reply
  Report
LuckyPiggie
·2022-02-23
Good news 👏
Reply
2
Report
Tik Tick
·2022-02-23
Great
Reply
5
Report
Fold Replies
- LuckyPiggie:
  ok
  2022-02-23
  Reply
  Report
ARIESan
·2022-02-23
That's good news
Reply
2
Report
Fold Replies
- LuckyPiggie:
  👍
  2022-02-23
  Reply
  Report
Jess261
·2022-02-23
Okay
Reply
2
Report
Fold Replies
- LuckyPiggie:
  great
  2022-02-23
  Reply
  Report
Gladys8jk
·2022-02-23
Ok
Reply
3
Report
Fold Replies
- LuckyPiggie:
  ok
  2022-02-23
  Reply
  Report
Cvt
·2022-02-22
Like
Reply
6
Report
Fold Replies
- LuckyPiggie:
  help
  2022-02-23
  Reply
  Report
来人
·2022-02-22
Nice
Reply
2
Report
Aaronboy
·2022-02-22
Like please
Reply
4
Report
Fold Replies
- DL97:
  Likezzz
  2022-02-23
  Reply
  Report
Success88
·2022-02-22
😊
Reply
4
Report
Fold Replies
- Nasbhai:
  Like pls
  2022-02-22
  Reply
  Report
- Cheekyd:
  please like 👍
  2022-02-22
  Reply
  Report
- Success88:
  Like done 😊
  2022-02-22
  Reply
  Report
DarkRaven
·2022-02-22
Ok
Reply
4
Report
shoude
·2022-02-22
Like and comment
Reply
4
Report
Fold Replies
- Cheekyd:
  please like 👍
  2022-02-22
  Reply
  Report
- JeremyKok:
  hi. please like and comment back. thank you.
  2022-02-22
  Reply
  Report
- shoude:
  2022-02-22
  Reply
  Report
V K
·2022-02-22
Pls like tyvm
Reply
6
Report
Fold Replies
- DarkRaven:
  Ok
  2022-02-22
  Reply
  Report
- JeremyKok:
  hi. please like and comment back. thank you.
  2022-02-22
  Reply
  Report

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1142064273?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-02-22 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142064273","market":"us","top_or_hot":-1,"title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","media":"Tiger Newspress","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1142064273","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","pubTimestamp":1645541268,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康早盘上涨逾2%，因乳腺癌治疗晚期数据积极","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":9030027198,"gmtCreate":1645583570649,"gmtModify":1676534042803,"author":{"id":"3576546636255665","authorId":"3576546636255665","name":"QQXTZ","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3576546636255665","authorIdStr":"3576546636255665"},"htmlText":"[Wow]&nbsp;[Like]&nbsp;[Like]&nbsp;","listText":"[Wow]&nbsp;[Like]&nbsp;[Like]&nbsp;","text":"[Wow] [Like] [Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9030027198","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100626791,"gmtCreate":1645601072801,"gmtModify":1663244194727,"authorId":4101354765322210,"author":{"id":4101354765322210,"idStr":"4101354765322210","authorId":4101354765322210,"name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030027198,"type":1,"supId":0,"prevId":0,"content":"👍👍","text":"👍👍","html":"👍👍"},{"id":100624774,"gmtCreate":1645584042514,"gmtModify":1663244187871,"authorId":4095668241594670,"author":{"id":4095668241594670,"idStr":"4095668241594670","authorId":4095668241594670,"name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030027198,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":9030029537,"gmtCreate":1645582460217,"gmtModify":1676534042612,"author":{"id":"4107063207857540","authorId":"4107063207857540","name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":6,"crmLevelSwitch":1,"idStr":"4107063207857540","authorIdStr":"4107063207857540"},"htmlText":"Good news 👏&nbsp;","listText":"Good news 👏&nbsp;","text":"Good news 👏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030029537","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030065876,"gmtCreate":1645581590624,"gmtModify":1676534042514,"author":{"id":"3573124416025977","authorId":"3573124416025977","name":"Tik Tick","avatar":"https://community-static.tradeup.com/news/f61bc2c16137d86022cc808c9bec9abd","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573124416025977","authorIdStr":"3573124416025977"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9030065876","repostId":1142064273,"repostType":2,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100624477,"gmtCreate":1645582488378,"gmtModify":1663244186732,"authorId":4107063207857540,"author":{"id":4107063207857540,"idStr":"4107063207857540","authorId":4107063207857540,"name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.04","exceedPercentage":"80.23%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030065876,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9030086120,"gmtCreate":1645579310586,"gmtModify":1676534042094,"author":{"id":"4087545408973980","authorId":"4087545408973980","name":"ARIESan","avatar":"https://static.tigerbbs.com/ab7b9364a4791173d66fbb5fda8ef925","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4087545408973980","authorIdStr":"4087545408973980"},"htmlText":"That's good news&nbsp;","listText":"That's good news&nbsp;","text":"That's good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9030086120","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100624479,"gmtCreate":1645582498444,"gmtModify":1663244186026,"authorId":4107063207857540,"author":{"id":4107063207857540,"idStr":"4107063207857540","authorId":4107063207857540,"name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.04","exceedPercentage":"80.23%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030086120,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":9030036884,"gmtCreate":1645576918806,"gmtModify":1676534041525,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9030036884","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100624481,"gmtCreate":1645582508159,"gmtModify":1663244185535,"authorId":4107063207857540,"author":{"id":4107063207857540,"idStr":"4107063207857540","authorId":4107063207857540,"name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.04","exceedPercentage":"80.23%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030036884,"type":1,"supId":0,"prevId":0,"content":"<u>great</u>","text":"<u>great</u>","html":"<u>great</u>"}],"langContent":"EN"},{"id":9030095390,"gmtCreate":1645576036258,"gmtModify":1676534041333,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9030095390","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100624482,"gmtCreate":1645582517543,"gmtModify":1663244186631,"authorId":4107063207857540,"author":{"id":4107063207857540,"idStr":"4107063207857540","authorId":4107063207857540,"name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.04","exceedPercentage":"80.23%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9030095390,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9097759200,"gmtCreate":1645572598534,"gmtModify":1676534039912,"author":{"id":"3579235597126488","authorId":"3579235597126488","name":"Cvt","avatar":"https://static.tigerbbs.com/c8fda02901ec7a98b51fe8e84d016ab2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579235597126488","authorIdStr":"3579235597126488"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9097759200","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100624484,"gmtCreate":1645582526189,"gmtModify":1663244185737,"authorId":4107063207857540,"author":{"id":4107063207857540,"idStr":"4107063207857540","authorId":4107063207857540,"name":"LuckyPiggie","avatar":"https://community-static.tradeup.com/news/33330ac1fe6d6c956e10045c870d6f46","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.04","exceedPercentage":"80.23%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097759200,"type":1,"supId":0,"prevId":0,"content":"<u>help</u>","text":"<u>help</u>","html":"<u>help</u>"}],"langContent":"EN"},{"id":9097760305,"gmtCreate":1645570011189,"gmtModify":1676534039402,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097760305","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097786383,"gmtCreate":1645569367597,"gmtModify":1676534039232,"author":{"id":"3586474193512687","authorId":"3586474193512687","name":"Aaronboy","avatar":"https://static.tigerbbs.com/875e45a6d6b604dfaa34ac175ccbbb29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586474193512687","authorIdStr":"3586474193512687"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9097786383","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100623098,"gmtCreate":1645576551757,"gmtModify":1663244177858,"authorId":3581595210484952,"author":{"id":3581595210484952,"idStr":"3581595210484952","authorId":3581595210484952,"name":"DL97","avatar":"https://static.tigerbbs.com/c5df17e476ae735a64e7017b160d3935","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097786383,"type":1,"supId":0,"prevId":0,"content":"Likezzz","text":"Likezzz","html":"Likezzz"}],"langContent":"EN"},{"id":9097714635,"gmtCreate":1645567872350,"gmtModify":1676534039055,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4101948424484190","authorIdStr":"4101948424484190"},"htmlText":"😊","listText":"😊","text":"😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9097714635","repostId":1142064273,"repostType":2,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100620867,"gmtCreate":1645568147434,"gmtModify":1663244171830,"authorId":4105706439484420,"author":{"id":4105706439484420,"idStr":"4105706439484420","authorId":4105706439484420,"name":"Nasbhai","avatar":"https://community-static.tradeup.com/news/fcdb00dbd2f786506cbba6840138e5ff","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097714635,"type":1,"supId":0,"prevId":0,"content":"Like pls","text":"Like pls","html":"Like pls"},{"id":100621100,"gmtCreate":1645569830590,"gmtModify":1663244170041,"authorId":4100179725007900,"author":{"id":4100179725007900,"idStr":"4100179725007900","authorId":4100179725007900,"name":"Cheekyd","avatar":"https://static.tigerbbs.com/05e7c6e8bcef8bb9fade899aca08288b","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097714635,"type":1,"supId":0,"prevId":0,"content":"please like 👍","text":"please like 👍","html":"please like 👍"},{"id":100621141,"gmtCreate":1645570119335,"gmtModify":1663244169639,"authorId":4101948424484190,"author":{"id":4101948424484190,"idStr":"4101948424484190","authorId":4101948424484190,"name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.28","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1,"categoryType":2007}]},"repliedAuthorId":0,"objectId":9097714635,"type":1,"supId":100621100,"prevId":0,"content":"Like done 😊","text":"Like done 😊","html":"Like done 😊"}],"langContent":"EN"},{"id":9097737122,"gmtCreate":1645565536382,"gmtModify":1676534038836,"author":{"id":"3578097586468199","authorId":"3578097586468199","name":"DarkRaven","avatar":"https://static.tigerbbs.com/f931425b992eebdac73826679fa69afc","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":8,"crmLevelSwitch":1,"idStr":"3578097586468199","authorIdStr":"3578097586468199"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097737122","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":638774705,"gmtCreate":1645550667139,"gmtModify":1676532753848,"author":{"id":"3587029173183468","authorId":"3587029173183468","name":"shoude","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3587029173183468","authorIdStr":"3587029173183468"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/638774705","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100621096,"gmtCreate":1645569816201,"gmtModify":1663244168933,"authorId":4100179725007900,"author":{"id":4100179725007900,"idStr":"4100179725007900","authorId":4100179725007900,"name":"Cheekyd","avatar":"https://static.tigerbbs.com/05e7c6e8bcef8bb9fade899aca08288b","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":638774705,"type":1,"supId":0,"prevId":0,"content":"please like 👍","text":"please like 👍","html":"please like 👍"},{"id":100620809,"gmtCreate":1645567748353,"gmtModify":1663244168037,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":638774705,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":7258354,"gmtCreate":1645550680997,"gmtModify":1663239865338,"authorId":3587029173183468,"author":{"id":3587029173183468,"idStr":"3587029173183468","authorId":3587029173183468,"name":"shoude","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":638774705,"type":1,"supId":0,"prevId":0,"content":"[呆住]","text":"[呆住]","html":"[呆住]"}],"langContent":"CN"},{"id":9097442791,"gmtCreate":1645542157965,"gmtModify":1676534037704,"author":{"id":"3577323914202336","authorId":"3577323914202336","name":"V K","avatar":"https://static.tigerbbs.com/536d624e5750dcffec704eeed9bc003b","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":7,"crmLevelSwitch":1,"idStr":"3577323914202336","authorIdStr":"3577323914202336"},"htmlText":"Pls like tyvm[Happy]&nbsp;","listText":"Pls like tyvm[Happy]&nbsp;","text":"Pls like tyvm[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9097442791","repostId":1142064273,"repostType":4,"repost":{"id":"1142064273","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645541268,"share":"https://ttm.financial/m/news/1142064273?lang=&edition=full_marsco","pubTime":"2022-02-22 22:47","market":"us","language":"en","title":"AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1142064273","media":"Tiger Newspress","summary":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.Th","content":"<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Rose Over 2% in Morning Trading on Positive Late-stage Data for Breast Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-22 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.<img src=\"https://static.tigerbbs.com/9e1858ea8115e7d34334e1ec70652d38\" tg-width=\"768\" tg-height=\"568\" width=\"100%\" height=\"auto\"/>The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142064273","content_text":"AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100620542,"gmtCreate":1645565528474,"gmtModify":1663244168335,"authorId":3578097586468199,"author":{"id":3578097586468199,"idStr":"3578097586468199","authorId":3578097586468199,"name":"DarkRaven","avatar":"https://static.tigerbbs.com/f931425b992eebdac73826679fa69afc","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.07","exceedPercentage":"93.96%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097442791,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":100620811,"gmtCreate":1645567760919,"gmtModify":1663244166947,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9097442791,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":204,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}